Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that can cause severe disease, including congenital birth defects during pregnancy 1 . To develop candidate therapeutic agents against ZIKV, we isolated a panel of human monoclonal antibodies from subjects that were previously infected with ZIKV. We show that a subset of antibodies recognize diverse epitopes on the envelope (E) protein and exhibit potent neutralizing activity. One of the most inhibitory antibodies, ZIKV-117, broadly neutralized infection of ZIKV strains corresponding to African and AsianAmerican lineages. Epitope mapping studies revealed that ZIKV-117 recognized a unique quaternary epitope on the E protein dimer-dimer interface. We evaluated the therapeutic efficacy of ZIKV-117 in pregnant and non-pregnant mice. Monoclonal antibody treatment markedly reduced tissue pathology, placental and fetal infection, and mortality in mice. Thus, neutralizing human antibodies can protect against maternal-fetal transmission, infection and disease, and reveal important determinants for structure-based rational vaccine design efforts.
to ZIKV E protein (EC 50 ) and neutralization (IC 50 ) of infection (Fig. 2a , Extended Data Fig. 1) ; most of the mAbs bound to E protein at low concentrations (EC 50 < 100 ng ml −1 ), whereas only four of the 29 mAbs exhibited strong neutralizing activity (IC 50 = 5-420 ng ml −1 ). We next determined how many antigenic sites on ZIKV E were recognized using quantitative competition binding. We identified four major competition groups (designated A, B, C or D). Group A mAbs had 23 members that were directed against the fusion loop in DII, as determined by differential binding to E and E-FLM (Extended Data Fig. 1 ), and had only one clone (ZIKV-88) with moderate neutralizing potency. The group B mAb ZIKV-116 neutralized ZIKV infection and bound to E, DIII and E-FLM. Group C mAbs bound to E and E-FLM weakly, but did not potently neutralize infection. The group D mAb ZIKV-195 neutralized with moderate potency and was similar in binding to both E and E-FLM. The most inhibitory group D mAb, ZIKV-117, bound to both E and E-FLM weakly.
We mapped the epitopes of representative mAbs using a shotgun alanine-scanning mutagenesis library 6 of ZIKV prM and E protein variants (Fig. 2b, Extended Data Fig. 2 ). Loss-of-binding analysis confirmed that group A mAbs bound to the fusion loop in DII, whereas the group B mAb bound to DIII. Group B mAb ZIKV-116 bound to an epitope involving residues T309, E393 and K394 along the lateral ridge of DIII (DIII-LR), which was confirmed in an ELISA that showed reduced binding to DIII with mutations A310E and T335K in DIII-LR 7 .
The epitope mapping studies suggest that the group D mAb ZIKV-117 binds specifically to DII across two adjacent dimers at the 'dimerdimer' interface (Fig. 2c ). We were unable to isolate virus neutralization escape mutant viruses for ZIKV-117, despite six passages in cell culture under mAb selection pressure.
Because of their potency, we assessed whether group B mAb ZIKV-116 and group D mAb ZIKV-117 could inhibit diverse ZIKV strains encompassing the African and Asian-American lineages. ZIKV-117 (Fig. 2d, e) . ZIKV-116 inhibited four of the five strains efficiently, but was inactive against MR 766, the original African strain (Fig. 2d, e) . Alignment of the sequences of ZIKV H/PF/2013 and MR 766, with respect to residues in DIII-LR 7 that ZIKV-116 binds, revealed only one difference (a conservative E393D change). Given these data, we hypothesize that the DIII-LR epitope of ZIKV-116 is displayed differently on MR 766 owing to allosteric effects of changes in other parts of the E protein, which could regulate epitope accessibility 8, 9 . As recent studies have suggested that cross-reactive ZIKV-specific human mAbs can enhance DENV infection in vivo 10 , we tested whether these two ZIKV-neutralizing mAbs could bind to DENV-infected cells. ZIKV-117 showed a restricted type-specific binding pattern as it failed to stain cells infected with DENV-1, DENV-2, DENV-3 or DENV-4, or bind to purified WNV E protein (Extended Data Fig. 3 and data not shown). In comparison, ZIKV-116 bound to cells infected with DENV-1, DENV-2 or DENV-4, but did not bind to DENV-2 DIII or WNV DIII in ELISA.
In vivo models of ZIKV pathogenesis and antibody prophylaxis have been reported 7, 10, 11 in mice deficient in type-I interferon signalling. To determine whether ZIKV-117 had therapeutic activity, we treated 4-5-week-old wild-type male C57BL/6 mice at day − 1 with antiIfnar1 mAbs, and then inoculated animals with 10 3 focus-forming units (FFU) of a mouse-adapted African strain of ZIKV-Dakar 7 . Animals were treated with a single dose of ZIKV-117 or non-binding isotype control (human (h)CHK-152) 12 , on day + 1 (100 μ g; 6.7 mg kg ). Animals treated with hCHK-152 sustained significant lethality compared to those receiving ZIKV-117 (Fig. 3a) , which were protected even when administered only a single dose 5 days after virus inoculation.
We and others have demonstrated placental injury and fetal demise following ZIKV infection of pregnant mice with deficiencies in type-I interferon signalling [13] [14] [15] . To assess the protective ability of ZIKV-117 during fetal development, we treated Ifnar1 −/− pregnant dams mated to wild-type male mice with a single 250 μ g dose of ZIKV-117 or isotype control mAb (hCHK-152) on embryo day 5.5 (E5.5), the day before ZIKV inoculation. Whereas inoculation with ZIKV-Brazil at E6.5 following administration with hCHK-152 resulted in high levels of maternal infection and almost uniform fetal demise by E13.5, treatment with ZIKV-117 improved fetal outcome (Fig. 3b, c) .
Because of the extent of demise at E13.5 after ZIKV infection of Ifnar1 −/− dams, we could not recover adequate numbers of fetuses to measure viral titres. Accordingly, we switched to a wild-type mouse model with an acquired type-I interferon deficiency using the mouseadapted African ZIKV-Dakar strain. Wild-type pregnant dams were treated at day − 1 (E5.5) with an anti-Ifnar1 mAbs. At the same time, these animals were administered vehicle control (PBS), 250 μ g isotype control hCHK-152, or 250 μ g ZIKV-117. One day later, dams were inoculated subcutaneously with 10 3 FFU of ZIKV-Dakar. Fetuses from dams treated with anti-Ifnar1 mAbs and given PBS or hCHK-152 showed high levels (for example, around 10 5 to 10 7 FFU equivalents per gram) of viral RNA in the placenta and fetal brain (Fig. 3d) . In comparison, mice treated with anti-Ifnar1 and ZIKV-117 had reduced virus levels in the placenta and fetal brain (for example, around 10° to 10 3 FFU equivalents per gram). This phenotype was associated with transport of human ZIKV E-specific IgG across the maternal-fetal placental barrier (816 ± 53 ng ml −1 for the placenta and 1,675 ± 203 ng ml −1 for the fetal head; Extended Data Fig. 4 ). As levels of neonatal Fc receptor in the mouse placenta are lower than other mammalian species 16 , reduced levels of transport of maternal or exogenous IgG into the fetus is expected 17 . Although this factor could underestimate the therapeutic effect of exogenous anti-ZIKV IgG or maternal antibodies, we nonetheless achieved levels in the placenta and fetal head that were orders of magnitude above the IC 50 neutralization value for ZIKV-117. of anti-Ifnar1 mAb followed by subcutaneous inoculation with 10 3 FFU of mouse-adapted ZIKV-Dakar. Mice were treated with a single 100 μ g or 250 μ g dose of isotype control mAb (hCHK-152) or ZIKV-117 on D+ 1 or D+ 5 (n = 10 per group from two independent experiments), respectively. Significance was analysed by the log-rank test (* P < 0.05; * * P < 0.01).
b, c, Ifnar1
−/− female mice were mated with wild-type sires. At E5.5, dams were treated with 250 μ g of either hCHK-152 isotype control mAb or ZIKV-117. Bars indicate the median values and reflect data pooled from four independent experiments. Significance for fetal survival and viral RNA was analysed by chi-square (b; * * * * P < 0.0001) and Mann-Whitney (c; * P < 0.05) tests, respectively. d-f, Wild-type female mice were mated with wild-type sires. At E5.5, dams were treated with anti-Ifnar1 mAb and one of the following: PBS (d, e), 250 μ g (d-f) of hCHK-152 isotype control mAb, 250 μ g of ZIKV-117 (d-f) or 250 μ g of ZIKV-117 LALA (f). At E6.5, dams were inoculated with 10 3 FFU of ZIKV-Dakar. d-f, Fetuses and placentas (d, f) and maternal brain and serum (e) were collected on E13.5 and viral RNA was measured by qRT-PCR. Bars indicate the median values of samples collected from three biological replicates (d, n = 20-36; e, n = 5-9; f, n = 23-28). Significance was analysed by ANOVA with a Dunn's multiple comparison test (* P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001). g, h, Wild-type female mice were mated with wild-type sires. At E5.5, dams were treated with anti-Ifnar1 mAb. At E6.5, dams were inoculated with 10 3 FFU of ZIKV-Dakar. At E7.5 (day + 1 after infection), dams were treated with PBS, 250 μ g of hCHK-152 isotype control mAb, or 250 μ g of ZIKV-117. g, h, Fetuses and placentas (g) and maternal brain and serum (h) were collected on E13.5 and viral RNA was measured by qRT-PCR. Bars indicate the median values of samples collected from three biological replicates (g, n = 8-20; h, n = 3-7). Significance was analysed by ANOVA with Dunn's (g) or Tukey's (h) multiple comparisons test (* P < 0.05, * * * P < 0.001, * * * * P < 0.0001). Dashed lines indicate the limit of detection of the assay. Dams treated with ZIKV-117 also had substantially lower levels of viral RNA in the maternal brain and serum (Fig. 3e) .
Antibody-dependent enhancement of flavivirus infection occurs when type-specific or cross-reactive antibodies fail to reach a stoichiometric threshold for neutralization and instead facilitate infection of Fcγ R-expressing myeloid cells 18 . Because antibodies can promote antibody-dependent enhancement of ZIKV in cell culture 19, 20 , we evaluated the protective efficacy of a recombinant form of ZIKV-117 IgG containing a leucine (L) to alanine (A) substitution at positions 234 and 235 (LALA) 21 , which lacked efficient binding to Fcγ R, retained interactions with FcRn
22
, and neutralized ZIKV in vitro equivalently compared to the parent mAb (Extended Data Fig. 5 ). The LALA variant of ZIKV-117 showed similar protective activity against infection of the placenta and fetus relative to the parent mAb (Fig. 3f) . As the protection conferred by ZIKV-117 in the pregnancy model is probably due to neutralization and not Fc effector functions, LALA variants could be used without a risk of antibody-dependent enhancement.
We next assessed the post-exposure efficacy of ZIKV-117 during pregnancy. Mice treated with anti-Ifnar1 mAbs at E5.5 were inoculated with 10 3 FFU of ZIKV-Dakar at E6.5 and then administered a single dose of PBS, 250 μ g of hCHK-152, or 250 μ g of ZIKV-117 at E7.5. Compared to PBS or isotype control mAb treatment, administration of ZIKV-117 markedly reduced the viral burden in the dams, the placenta and fetus when measured at E13.5 (Fig. 3g, h ).
The reduction in viral load mediated by ZIKV-117 was associated with decreased damage of the placenta (as judged by labyrinth layer and overall placenta area), less trophoblast cell death, and increased body size of the fetus (Fig. 4a-c) compared to fetuses of PBS-or hCHK-152-treated dams. ZIKV-117 protected against ZIKV-induced placental insufficiency, as the placental area and fetal size from infected dams treated with anti-ZIKV mAbs were similar to that of uninfected placentas 14 . In situ hybridization revealed an almost complete absence of viral RNA in the junctional zone and decidua of the placenta in animals treated with ZIKV-117 compared to staining observed in PBS-or hCHK-152-treated controls (Fig. 4d, Extended Data Fig. 6 ). We also observed vascular damage associated with ZIKV infection of the placenta 14 , characterized as diminished vimentin staining of fetal endothelial cells, which was rescued by ZIKV-117 to levels seen in uninfected placentas (Fig. 4e) . The histopathological data suggests that ZIKV-117 treatment can reduce the ability of ZIKV to cross the fetal endothelial cell barrier, and thereby prevent vertical transmission and improve fetal outcome.
Our most potent neutralizing antibodies exhibited a breadth of inhibitory activity against strains from Africa, Asia, and the Americas. Even a single ZIKV-117 dose given 5 days after infection protected mice against lethal infection, a timeline similar to the most protective antibodies against other flaviviruses 23 . Prophylaxis or post-exposure therapy of pregnant mice with ZIKV-117 reduced infection in mothers, 
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Research subjects. We studied eight subjects in the United States with previous or recent ZIKV infection (Extended Data Table 2 ). The studies were approved by the Institutional Review Board of Vanderbilt University Medical Center; samples were obtained after informed consent was obtained by the Vanderbilt Clinical Trials Center. Two subjects (972 and 973) were infected with an African lineage strain in 2008 (one subject while working in Senegal, the second acquired the infection by sexual transmission from the first, as previously reported 24 ). The other six subjects were infected during the current outbreak of an Asian lineage strain, following exposure in Brazil, Mexico or Haiti. Generation and quantification of human B-cell lines secreting ZIKV E protein specific antibodies. Peripheral blood mononuclear cells (PBMCs) from heparinized blood were isolated with Ficoll-Histopaque by density gradient centrifugation. The cells were used immediately or cryopreserved in the vapour phase of liquid nitrogen until use. Ten million PBMCs were cultured in 384-well plates (Nunc) using culture medium (ClonaCell-HY Medium A, StemCell Technologies) supplemented with 8 μ g ml −1 of the TLR agonist CpG (phosphorothioate-modified oligodeoxynucleotide ZOEZOEZZZZZOEEZOEZZZT, Invitrogen), 3 μ g ml −1 of Chk2 inhibitor (Sigma), 1 μ g ml −1 of cyclosporine A (Sigma), and clarified supernatants from cultures of B95.8 cells (ATCC) containing Epstein-Barr virus. After 7 days, cells from each 384-well culture plate were expanded into four 96-well culture plates (Falcon) using ClonaCell-HY Medium A containing 8 μ g ml −1 of CpG, 3 μ g ml
of Chk2 inhibitor, and 10 7 irradiated heterologous human PBMCs (Nashville Red Cross) and cultured for an additional 4 days. Supernatants were screened in ELISA (described below) for reactivity with various ZIKV E proteins, which are described below. The minimal frequency of ZIKV E-reactive B cells was estimated based on the number of wells with E protein-reactive supernatants compared with the total number of lymphoblastoid cell line colonies in the transformation plates (calculation: E-reactive B-cell frequency = (number of wells with E-reactive supernatants) divided by (number of LCL colonies in the plate) × 100). Protein expression and purification. The ectodomains of ZIKV E (H/PF/2013; GenBank Accession KJ776791) and the fusion-loop mutant E-FLM (containing four mutations: T76A, Q77G, W101R, L107R) were expressed transiently in Expi293F cells and purified as described previously 7 . ZIKV DIII (residues 299-407 of strain H/PF/2013), WNV DIII (residues 296-405 of strain New York 1999) and DENV-2 DIII (residues 299-410 of strain 16681) were expressed in BL21 (DE3) as inclusion bodies and refolded in vitro 25 . Briefly, inclusion bodies were denatured and refolded by gradual dilution into a refolding buffer (400 mM l-arginine, 100 mM Tris (pH 8.3), 2 mM EDTA, 5 and 0.5 mM reduced and oxidized glutathione) at 4 °C. Refolded proteins were purified by size-exclusion chromatography using a Superdex 75, 16/60 (GE Healthcare). Generation of human hybridomas. Cells from wells with transformed B cells containing supernatants that exhibited reactivity to ZIKV E protein were fused with HMMA2.5 myeloma cells (gift from L. Cavacini) using an established electrofusion technique 26 . After fusion, hybridomas were suspended in a selection medium containing 100 μ M hypoxanthine, 0.4 μ M aminopterin, 16 μ M thymidine (HAT Media Supplement, Sigma), and 7 μ g ml −1 ouabain (Sigma) and cultured in 384-well plates for 18 days before screening hybridomas for antibody production by ELISA. After fusion with HMMA2.5 myeloma cells, hybridomas producing ZIKV E-specific antibodies were cloned biologically by single-cell fluorescence-activated cell sorting. Hybridomas were expanded in post-fusion medium (ClonaCell-HY Medium E, STEMCELL Technologies) until 50% confluent in 75-cm 2 flasks (Corning).
For antibody production, cells from one 75-cm 2 flask were collected with a cell scraper and expanded to four 225-cm 2 flasks (Corning) in serum-free medium (Hybridoma-SFM, Life Technologies). After 21 days, supernatants were clarified by centrifugation and filtered using 0.45-μ m pore size filter devices. HiTrap Protein G or HiTrap MabSelectSure columns (GE Healthcare Life Sciences) were used to purify antibodies from filtered supernatants. Sequence analysis of antibody variable region genes. Total cellular RNA was extracted from pelleted cells from hybridoma clones, and an RT-PCR reaction was performed using mixtures of primers designed to amplify all heavy-chain or light-chain antibody variable regions 27 . The generated PCR products were purified using AMPure XP magnetic beads (Beckman Coulter) and sequenced directly using an ABI3700 automated DNA sequencer. The variable region sequences of the heavy and light chains were analysed using the IMGT/V-Quest program 28, 29 . ELISA and EC 50 binding analysis. Wells of microtitre plates were coated with purified, recombinant ectodomain of ZIKV E, DIII, DIII-LR mutants (DIII containing A310E and T335K mutations) or DIII of related flaviviruses DENV-2 or WNV and incubated at 4 °C overnight. In ELISA studies with purified mAbs, we used recombinant ZIKV E protein ectodomain with His 6 tag produced in Sf9 insect cells (Meridian Life Sciences R01635). Plates were blocked with 5% skimmed milk in PBS-T for 1 h. B-cell culture supernatants or purified antibodies were added to the wells and incubated for 1 h at ambient temperature. The bound antibodies were detected using goat anti-human IgG (γ -specific) conjugated with alkaline phosphatase (Southern Biotech) and pNPP disodium salt hexahydrate substrate (Sigma). In ELISAs that assessed binding of mAbs to DIII and DIII LR mutants, we used previously described murine mAbs ZV-2 and ZV-54 (ref. 7) as controls. A goat anti-mouse IgG conjugated with alkaline phosphatase (Southern Biotech) was used for detection of these antibodies. Colour development was monitored at 405 nm in a spectrophotometer (Biotek). For determining EC 50 , microtitre plates were coated with ZIKV E or E-FLM that eliminated interaction of fusion-loop specific antibodies. Purified antibodies were diluted serially and applied to the plates. Bound antibodies were detected as above. A nonlinear regression analysis was performed on the resulting curves using Prism (GraphPad) to calculate EC 50 values. ELISA for detection of human antibodies in murine tissues. Fetal head and placental tissues were collected at E13.5 from groups treated with ZIKV-117 or PBS (as a negative control), homogenized in PBS (250 μ l) and stored at − 20 °C. ELISA plates were coated with ZIKV E protein, and thawed, clarified tissue homogenates were applied undiluted in triplicate. Bound antibodies were detected using goat anti-human IgG (Fc-specific) antibody conjugated with alkaline phosphatase. The quantity of antibody was determined by comparison with a standard curve constructed using purified ZIKV-117 in a dilution series. Biolayer interferometry competition binding assay. His 6 -tagged ZIKV E protein was immobilized on anti-His coated biosensor tips (Pall) for 2 min on an Octet Red biosensor instrument. After measuring the baseline signal in kinetics buffer (PBS, 0.01% BSA, and 0.002% Tween 20) for 1 min, biosensor tips were immersed into the wells containing first antibody at a concentration of 10 μ g ml −1 for 7 min. Biosensors then were immersed into wells containing a second mAb at a concentration of 10 μ g ml −1 for 7 min. The signal obtained for binding of the second antibody in the presence of the first antibody was expressed as a percentage of the uncompeted binding of the second antibody that was derived independently. The antibodies were considered competing if the presence of first antibody reduced the signal of the second antibody to less than 30% of its maximal binding and non-competing if the signal was greater than 70%. A level of 30-70% was considered intermediate competition.
Shotgun mutagenesis epitope mapping. Epitope mapping was performed by shotgun mutagenesis essentially as described previously 6 . A ZIKV prM/E protein expression construct (based on ZIKV strain SPH2015) was subjected to high-throughput alanine scanning mutagenesis to generate a comprehensive mutation library. Each residue within prM/E was changed to alanine, with alanine codons mutated to serine. In total, 672 ZIKV prM/E mutants were generated (100% coverage), sequence confirmed, and arrayed into 384-well plates. Each ZIKV prM/E mutant was transfected into HEK-293T cells and allowed to express for 22 h. Cells were fixed in 4% (v/v) paraformaldehyde (Electron Microscopy Sciences), and permeabilized with 0.1% (w/v) saponin (Sigma-Aldrich) in PBS plus calcium and magnesium (PBS+ + ). Cells were incubated with purified mAbs diluted in PBS+ + , 10% normal goat serum (Sigma), and 0.1% saponin. Primary antibody screening concentrations were determined using an independent immunofluorescence titration curve against wild-type ZIKV prM/E to ensure that signals were within the linear range of detection. Antibodies were detected using 3.75 μ g ml
of AlexaFluor488-conjugated secondary antibody (Jackson ImmunoResearch Laboratories) in 10% NGS/0.1% saponin. Cells were washed three times with PBS+ + /0.1% saponin followed by two washes in PBS. Mean cellular fluorescence was detected using a high-throughput flow cytometer (HTFC, Intellicyt). Antibody reactivity against each mutant prM/E clone was calculated relative to wild-type prM/E protein reactivity by subtracting the signal from mock-transfected controls and normalizing to the signal from wild-type prM/E-transfected controls. Mutations within clones were identified as critical to the mAb epitope if they did not support reactivity of the test MAb, but supported reactivity of other ZIKV antibodies. This counter-screen strategy facilitates the exclusion of prM/E mutants that are locally misfolded or have an expression defect. , or positive (hE60) 30 isotype controls. After washing, cells were incubated with Alexa-Fluor-647-conjugated goat anti-human IgG (Invitrogen) at 1:500, fixed in 1% PFA in PBS, processed on MACSQuant Analyzed (Miltenyi Biotec), and analysed using FlowJo software (Tree Star). Recombinant antibody expression and purification. Total RNA was extracted from hybridoma cells and genes encoding the VH and VL domains were amplified in RT-PCR using IgExp primers 31 . The PCR products were directly cloned into antibody expression vectors containing the constant domains of wild-type γ 1 chain, LALA mutant (leucine (L) to alanine (A) substitution at positions 234 and 235) γ 1 chain for the VH domains, and wild-type κ chain for the VL domain in an isothermal amplification reaction (Gibson reaction) 32 . Plasmids encoding the heavy and light chain were transfected into 293F cells and full-length recombinant IgG was secreted into transfected cell supernatants. Supernatants were collected and IgG purified using Protein G chromatography and eluted into PBS. The functional abrogation of the binding of the LALA variant IgG was confirmed in an ELISA binding assay with recombinant human Fcγ RI. The binding of wild-type ZIKV-117 or LALA antibody to Fcγ RI was evaluated, in comparison with the binding pattern of control antibodies (human mAb CKV063 (ref. 33) LALA mutated IgG). Adult mouse lethal protection experiments. C57BL/6 male mice (4-5-week-old, Jackson Laboratories) were inoculated with 10 3 FFU of mouse-adapted ZIKV-Dakar by subcutaneous route in the footpad. One-day before infection, mice were treated with 2 mg anti-Ifnar1 mAb (MAR1-5A3, Leinco Technologies) by intraperitoneal injection. ZIKV-specific human mAb (ZIKV-117) or an isotype control (hCHK-152) was administered as a single dose at day + 1 (100 μ g) or day + 5 (250 μ g) after infection through an intraperitoneal route. Animals were monitored for 21 days. Pregnant mouse protection experiments. Wild-type C57BL/6 mice were bred in a specific pathogen-free facility at Washington University School of Medicine.
(1) Ifnar1 −/− dams, prophylaxis studies: Ifnar1 −/− female and wild-type male mice were mated; at E5.5, dams were treated with a single 250 μ g dose of ZIKV mAb or isotype control by intraperitoneal injection. At E6.5, mice were inoculated with 10 3 FFU of ZIKV Brazil Paraiba 2015 by subcutaneous injection in the footpad. (2) Wild-type dams, prophylaxis studies: wild-type female and male mice were mated; at embryonic days E5.5, dams were treated with a single 250 μ g dose of ZIKV mAb or isotype control by intraperitoneal injection as well as a 1 mg injection of anti-Ifnar1 (MAR1-5A3). At E6.5, mice were inoculated with 10 3 FFU of mouse-adapted ZIKV-Dakar by subcutaneous injection in the footpad. At E7.5, dams received a second 1 mg dose of anti-Ifnar1 through an intraperitoneal route.
(3) Wild-type dams, therapy studies: wild-type female and male mice were mated; at embryonic days E5.5, dams were treated with a 1 mg injection of anti-Ifnar1 (MAR1-5A3). At E6.5, mice were inoculated with mouse-adapted 10 3 FFU of ZIKV-Dakar by subcutaneous injection in the footpad. At E7.5, dams received a second 1 mg dose of anti-Ifnar1 as well as a single 250 μ g dose of ZIKV mAb or isotype control through an intraperitoneal route. All animals were euthanized at E13.5, and placentas, fetuses and maternal tissues were collected. Fetus size was measured as the crown-rump length × occipitofrontal diameter of the head. Measurement of viral burden. ZIKV-infected tissues were weighed and homogenized with stainless steel beads in a Bullet Blender instrument (Next Advance) in 200 μ l of PBS. Samples were clarified by centrifugation (2,000g for 10 min). All homogenized tissues from infected animals were stored at − 20 °C. Tissue samples and serum from ZIKV-infected mice were extracted with RNeasy 96 Kit (tissues) or Viral RNA Mini Kit (serum) (Qiagen). ZIKV RNA levels were determined by TaqMan one-step quantitative reverse transcriptase PCR (qRT-PCR) on an ABI7500 Fast Instrument using published primers and conditions 34 . Viral burden was expressed on a log 10 scale as viral RNA equivalents per g or ml after comparison with a standard curve produced using serial tenfold dilutions of ZIKV RNA. Viral RNA in situ hybridization. RNA in situ hybridization was performed with RNAscope 2.5 (Advanced Cell Diagnostics) according to the manufacturer's instructions. PFA-fixed paraffin embedded placental sections were deparaffinized by incubation for 60 min at 60 °C. Endogenous peroxidases were quenched with H 2 O 2 for 10 min at room temperature. Slides were boiled for 15 min in RNAscope Target Retrieval Reagents and incubated for 30 min in RNAscope Protease Plus before probe hybridization. The probe targeting ZIKV RNA was designed and synthesized by Advanced Cell Diagnostics (catalogue number 467771). Negative (targeting bacterial gene dapB) control probes were also obtained from Advanced Cell Diagnostics (catalogue number 310043). Tissues were counterstained with Gill's haematoxylin and visualized with standard bright-field microscopy. Histology and immunohistochemistry. Collected placentas were fixed in 10% neutral buffered formalin at room temperature and embedded in paraffin. At least three placentas from different litters with the indicated treatments were sectioned and stained with haematoxylin and eosin to assess morphology. Surface area and thickness of placenta and different layers were measured using Image J software. For immunofluorescence staining on mouse placentas, deparaffinized tissues were blocked in blocking buffer (1% BSA, 0.3% Triton, PBS) for 2 h and incubated with anti-vimentin antibody (1:500, rabbit, Abcam ab92547). Secondary antibody conjugated with Alexa 488 (1:500 in PBS) was applied for 1 h at room temperature. Samples were counterstained with DAPI (4′ 6′ -diamidino-2-phenilindole, 1:1,000 dilution). Statistical analysis. All virological data were analysed with GraphPad Prism software. Kaplan-Meier survival curves were analysed by the log rank test, and viraemia was compared using an ANOVA with a multiple comparisons test. P < 0.05 indicated statistically significant differences. Data availability. All relevant data are included with the manuscript; source data for each of the main text figures is provided.
